Research graph
References from Age-stratified adverse-event reporting signals of seven ALK/ROS1 tyrosine kinase inhibitors in FAERS: a disproportionality and time to onset study. Local targets link to admitted publications; unresolved targets remain external evidence.
A bayesian neural network method for adverse drug reaction signal generation
10.1007/s002280050466 · 1998 · External reference
Controlling the false discovery rate: a practical and powerful approach to multiple testing
10.1111/j.2517-6161.1995.tb02031.x · 1995 · External reference
Brigatinib versus crizotinib in ALK inhibitor–naive advanced ALK-positive NSCLC: final results of phase 3 ALTA-1L trial
10.1016/j.jtho.2021.07.035 · 2021 · External reference
Emerging toxicities of antibody-drug conjugates for breast cancer: clinical prioritization of adverse events from the FDA adverse event reporting system
10.1007/s11523-024-01058-9 · 2024 · External reference
Repotrectinib in ROS1 fusion–positive non–small-cell lung cancer
10.1056/nejmoa2302299 · 2024 · External reference
Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system
10.1080/00031305.1999.10474456 · 1999 · External reference
Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports
10.1002/pds.677 · 2001 · External reference
The reporting of a disproportionality analysis for drug safety signal detection using individual case safety reports in PharmacoVigilance (READUS-PV): development and statement
10.1007/s40264-024-01421-9 · 2024 · External reference
Replication of the weber effect using postmarketing adverse event reports voluntarily submitted to the United States food and drug administration
10.1592/phco.24.8.743.36068 · 2004 · External reference
Use of larotrectinib in a pediatric patient with NTRK -rearranged spindle cell neoplasm and subsequent recurring bone fracture
10.1002/pbc.30679 · 2023 · External reference
Estimating time-to-onset of adverse drug reactions from spontaneous reporting databases
10.1186/1471-2288-14-17 · 2014 · External reference
Factors associated with age disparities among cancer clinical trial participants
10.1001/jamaoncol.2019.2055 · 2019 · External reference
Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications
10.1046/j.1365-2125.2003.02007.x · 2004 · External reference
Impact of safety alerts on measures of disproportionality in spontaneous reporting databases: the notoriety bias
10.2165/00002018-200730100-00007 · 2007 · External reference
Channeling bias in the interpretation of drug effects
10.1002/sim.4780100409 · 1991 · External reference
Commonality of drug-associated adverse events detected by 4 commonly used data mining algorithms
10.7150/ijms.7967 · 2014 · External reference
Core concepts in pharmacoepidemiology: confounding by indication and the role of active comparators
10.1002/pds.5407 · 2022 · External reference
Enzyme-transporter-mediated drug interactions with small molecule tyrosine kinase inhibitors
10.1002/jps.24113 · 2014 · External reference
Crizotinib in ROS1 -rearranged non–small-cell lung cancer
10.1056/nejmoa1406766 · 2014 · External reference
First-line lorlatinib or crizotinib in advanced ALK -positive lung cancer
10.1056/nejmoa2027187 · 2020 · External reference
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
10.1038/nature05945 · 2007 · External reference
First-line crizotinib versus chemotherapy in ALK -positive lung cancer
10.1056/nejmoa1408440 · 2014 · External reference
Roles of neurotrophins in skeletal tissue formation and healing
10.1002/jcp.25936 · 2018 · External reference
Unresolved reference
External reference
Drug–drug interactions with tyrosine-kinase inhibitors: a clinical perspective
10.1016/s1470-2045(13)70579-5 · 2014 · External reference
A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions
10.1002/pds.668 · 2002 · External reference
Analysis of age-specific adverse events with vancomycin: a real-world pharmacovigilance study based on the FAERS database
10.1097/js9.0000000000004563 · 2026 · External reference
Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth
10.1158/1535-7163.mct-11-0264 · 2011 · External reference
From class effects to specificity FAERS evidence and network mapping of adverse events in NSCLC targeted therapy
10.1097/js9.0000000000004704 · 2026 · External reference
Expert consensus of management of adverse drug reactions with anaplastic lymphoma kinase tyrosine kinase inhibitors
10.1016/j.esmoop.2023.101560 · 2023 · External reference
